Lenalidomide Stada Nordic (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s substrate specificity, leading to the degradation of transcription factors such as Ikaros and Aiolos. The result is reduced tumor cell proliferation, inhibition of angiogenesis, and modulation of the immune response, which together contribute to its anti‑cancer effects.

The specific dose of lenalidomide is individualized by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Healthcare providers determine the appropriate regimen and any necessary adjustments, so patients should follow the exact dosing instructions provided by their treating physician.

Lenalidomide is classified as having unknown pregnancy category and is considered teratogenic. It should not be used by pregnant women, and both male and female patients must use effective contraception during treatment and for a defined period after stopping therapy. Breastfeeding is not recommended because the drug may be excreted in milk and could harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Lenalidomide shares the same class as thalidomide and pomalidomide but generally offers a more favorable safety profile, with lower rates of peripheral neuropathy compared with thalidomide. Pomalidomide is often reserved for patients who have progressed after lenalidomide therapy. Efficacy varies by disease context, and the choice of agent depends on prior treatment history, tolerability, and specific clinical goals.

Store Lenalidomide tablets at temperatures below 25 °C in a dry environment. Keep the product in its original blister pack or container to protect it from moisture and light. Do not store in bathrooms or near heat sources. If the packaging is damaged, discard the medication according to local regulations.

Lenalidomide is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a full glass of water and not chewed, crushed, or split unless specifically instructed by a healthcare professional. Adherence to the prescribed schedule is important for optimal therapeutic effect.

Serious risks include severe neutropenia, which can lead to life‑threatening infections; venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism; secondary primary malignancies; and rare but severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for signs of infection, unusual bruising, swelling, or skin changes, and report any concerns promptly.

Lenalidomide should not be used by individuals with known hypersensitivity to the drug or its excipients, pregnant women, or patients who cannot adhere to strict contraception requirements. Caution is advised for patients with severe renal impairment who have not had dose adjustments, and for those with a history of thromboembolic events unless appropriate prophylaxis is in place.